

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

Recombinant Anti-CD4 antibody [EPR6855] - BSA and Azide free

RRID:AB_2864377

Type: Antibody

Proper Citation

Abcam Cat# ab181724, RRID:AB_2864377

Antibody Information

URL: http://antibodyregistry.org/AB_2864377

Proper Citation: Abcam Cat# ab181724, RRID:AB_2864377

Target Antigen: CD4

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IMC™, ICC/IF, Flow Cyt, IHC-P

Antibody Name: Recombinant Anti-CD4 antibody [EPR6855] - BSA and Azide free

Description: This recombinant targets CD4

Target Organism: human

Clone ID: EPR6855

Antibody ID: AB_2864377

Vendor: Abcam

Catalog Number: ab181724

Record Creation Time: 20250820T033816+0000

Record Last Update: 20250820T164715+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD4 antibody [EPR6855] - BSA and Azide free.

No alerts have been found for Recombinant Anti-CD4 antibody [EPR6855] - BSA and Azide free.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Marceaux C, et al. (2026) TNF- α -mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma. *Cell reports. Medicine*, 7(2), 102593.

Meylan M, et al. (2026) Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. *Cell*, 189(5), 1287.

Vuong L, et al. (2026) Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. *Cancer cell*, 44(7), 1477.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Liu Y, et al. (2025) Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. *Cancer cell*, 43(5), 905.

Eling N, et al. (2025) Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan. *Cell reports methods*, 5(9), 101170.

Barlow GL, et al. (2025) The extra-islet pancreas supports autoimmunity in human type 1 diabetes. *eLife*, 13.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. *Cancer cell*, 43(6), 1125.

Bost P, et al. (2025) Statistical modeling and analysis of cell counts from multiplexed imaging data. *Cell systems*, 16(6), 101296.

Cords L, et al. (2024) Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. *Cancer cell*, 42(3), 396.

Baars MJD, et al. (2024) Multiplex spatial omics reveals changes in immune-epithelial crosstalk during inflammation and dysplasia development in chronic IBD patients. *iScience*, 27(8), 110550.

van Eijs MJM, et al. (2023) Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis. *iScience*, 26(10), 107891.

Mascharak S, et al. (2023) Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. *Cell reports. Medicine*, 4(11), 101248.

Baharlou H, et al. (2022) An in situ analysis pipeline for initial host-pathogen interactions reveals signatures of human colorectal HIV transmission. *Cell reports*, 40(12), 111385.

Miheecheva N, et al. (2022) Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. *Cell reports*, 40(7), 111180.

Krop J, et al. (2022) Imaging mass cytometry reveals the prominent role of myeloid cells at the maternal-fetal interface. *iScience*, 25(7), 104648.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Strand SH, et al. (2022) Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. *Cancer cell*, 40(12), 1521.

Ferrian S, et al. (2021) Multiplexed imaging reveals an IFN- γ -driven inflammatory state in nivolumab-associated gastritis. *Cell reports. Medicine*, 2(10), 100419.